Program Description
Lymphoma, including diffuse
large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), often becomes
relapsed/refractory despite standard chemotherapy or targeted therapies and
requires novel therapeutic approaches. Bispecific antibodies (BsAbs) represent
a significant advancement, yet their complex administration, potential for
serious adverse effects, and the increasing trend toward community-based
administration pose significant challenges for oncology pharmacists. As BsAbs
gain approval for earlier lines of therapy and more indications, their use is
shifting to community pharmacies and clinics. For these reasons, it is
pharmacists within community cancer settings who frequently serve as the link
between the oncology clinic and local hospitals and support the coordinated
care of patients with DLBCL and FL. This webinar will equip oncology
pharmacists to navigate the evolving landscape of BsAbs by exploring recent FDA
approvals and clinical evidence for agents across different lines of therapy.
Practical approaches for personalizing treatment plans, using tools for
toxicity monitoring, implementing infection prophylaxis protocols, and leading
comprehensive patient and caregiver education to ensure safe and effective use
of BsAbs will be emphasized.
Target Audience: Oncology Pharmacist
Type of Activity: Application
Release date: December
19, 2025
Expiration date: December
19, 2026
Learner
level: Foundational
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the evolving role of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory (R/R) lymphomas, including recent FDA approvals, expanded indications, and updates to clinical guidelines.
- Optimize personalized treatment plans for patients with lymphoma involving the application of BsAbs.
- Analyze evidence-based approaches for monitoring, prevention, and management of common and serious AEs associated with BsAbs.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here